APPLICATION
This disclosure presents embodiments of novel strains of Staphylococcus aureus that through genetic engineering produce type 5 capsular polysaccharide at greater levels than Staphylococcus aureus strain Reynolds.
CLAIMS
- An isolated deoxyribonucleic acid sequence comprising SEQ ID NO: 7.
- A strain of Staphylococcus aureus comprising the isolated deoxyribonucleic acid sequence of claim 1.
- A strain of Staphylococcus aureus comprising an isolated DNA sequence comprising the cap1 promoter operably linked to the genes of the cap5 operon wherein the genes of the cap5 operon comprise the genes cap5A through cap5O as listed in SEQ ID NO: 7.
- A strain of Staphylococcus aureus comprising an isolated DNA sequence, said DNA sequence comprising a constitutive promoter wherein said constitutive promoter is operably linked to a cap5 operon wherein said constitutive promoter is the cap1 promoter of Staphylococcus aureus strain M comprising SEQ ID NO: 2, and wherein the cap1 promoter and cap5 operon comprise the deoxyribonucleic acid sequence SEQ ID NO: 7.